Cologne Placenta Cohort (CPC)
- Conditions
- Obesity, MaternalGestational Diabetes Mellitus in Pregnancy
- Interventions
- Other: no intervention
- Registration Number
- NCT05424965
- Lead Sponsor
- Sarah Appel
- Brief Summary
Aim of the study was to determine if signaling pathways in placentas of mothers affected by overweight/obesity or by gestational diabetes are altered compared to placentas of a control group (normal weight, no gestational diabetes). Moreover, maternal blood and umbilical cord blood were analysed.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- Female
- Target Recruitment
- 247
- singleton pregnancy
- BMI before pregnancy >= 18
- with & without gestational diabetes
- c-section at gestational week 35+0 until 41+6
- multiple pregnancy
- maternal serious internal disease
- infections before pregnancy (e.g. HIV, hepatitis B)
- pregnancy-associates diseases (e.g. gestoses, androgen insensitivity syndrome)
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description obese without gestational diabetes no intervention BMI \>= 30; normal glucose tolerance normal weight with gestational diabetes no intervention BMI \< 25; impaired oral glucose tolerance overweight with gestational diabetes no intervention BMI 25 - 29.9; impaired glucose tolerance overweight without gestational diabetes no intervention BMI 25 - 29.9; normal glucose tolerance obese with gestational diabetes no intervention BMI \>= 30; impaired glucose tolerance normal weight without gestational diabetes no intervention BMI \< 25; normal glucose tolerance
- Primary Outcome Measures
Name Time Method Activity of Wnt signaling pathway in placental tissue through study completion, about 4 years in total Analysis of components of the Wnt signaling pathway; like LRP6 receptor, beta-Catenin, GSK3beta, Wnt ligands (=proteins of interest) and an appropriate protein for normalization.
Total protein lysates of placental tissue will be used. Analysis will be performed by western blotting and subsequent densitometric analysis. Outcome measure will be \[relative protein level of protein or interest/relative protein level of normalization protein\].
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
University Hospital of Cologne
🇩🇪Cologne, NRW, Germany